Abbott Laboratories (NYSE:ABT) Price Target Cut to $119.00 by Analysts at Leerink Partners

Abbott Laboratories (NYSE:ABT) had its price target decreased by investment analysts at Leerink Partners from $136.00 to $119.00 in a research note issued on Friday,MarketScreener reports. The firm presently has a “market perform” rating on the healthcare product maker’s stock. Leerink Partners’ price objective points to a potential upside of 8.86% from the stock’s current price.

Other research analysts also recently issued reports about the company. Daiwa Capital Markets cut their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday. Mizuho upped their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Argus cut their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $138.40.

Abbott Laboratories Price Performance

ABT opened at $109.31 on Friday. The company’s 50-day simple moving average is $122.77 and its two-hundred day simple moving average is $127.49. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The stock has a market capitalization of $190.08 billion, a P/E ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Trading of Abbott Laboratories

Several hedge funds have recently bought and sold shares of ABT. IMG Wealth Management Inc. grew its stake in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the 4th quarter worth approximately $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the 3rd quarter worth $31,000. Finally, Anfield Capital Management LLC lifted its position in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.